Cell Metabolism News and Research

RSS

Animal study shows insulin prevents artery damage

Long suspected of worsening artery damage in patients with diabetes, insulin instead protects blood vessels, a new study by Joslin Diabetes Center scientists indicates.

5 May 2010

Agios Pharmaceuticals presents data on cancer-associated IDH1 mutations at 101st AACR meeting

Agios Pharmaceuticals, a biopharmaceutical company focused on discovering and developing novel drugs in the field of cancer metabolism, today announced multiple presentations at the American Association for Cancer Research (AACR) 101st Annual Meeting that highlight cancer metabolism as an approach to identify new ways to treat cancer, opening the potential for a new class of cancer drugs targeting metabolic enzymes.

22 Apr 2010

Celgene, Agios Pharmaceuticals form global strategic collaboration on targeting cancer metabolism

Celgene Corporation and Agios Pharmaceuticals Inc., a privately-held biotechnology company, today announced the formation of a global strategic collaboration focused on targeting cancer metabolism. The goal of the collaboration is to discover, develop, and deliver novel disease-altering therapies in oncology based on the transformational science of Agios' innovative cancer metabolism research platform. This platform is based on the concept that targeting key metabolic enzymes unique to rapidly proliferating cancer cells can "starve" the cancer.

15 Apr 2010

Hormones leptin and insulin work together to affect regulation of blood sugar levels, female fertility

New findings by UT Southwestern Medical Center researchers suggest that the hormones leptin and insulin work together in specific neurons in the hypothalamus region of the brain to affect both the regulation of blood sugar levels in the body and, surprisingly, female fertility.

12 Apr 2010

UCCS, Texas A&M Health Science Center announce collaboration in bioenergetics, immunology and cell life

The University of Colorado at Colorado Springs will work collaboratively with the Texas A&M Health Science Center in the areas of bioenergetics, immunology and cell life, according to a memorandum of understanding between the two schools announced Monday, April 10.

12 Apr 2010

Blood glucose-lowering hormone FGF21 also activates brown adipose tissue metabolism

The blood glucose-lowering hormone FGF21 is also an activator of brown adipose tissue metabolism, according to the study featured on the cover of Cell Metabolism and directed by the lecturer Francesc Villarroya of the UB's Department of Biochemistry and Molecular Biology (Faculty of Biology), the Institute of Biomedicine, and the Biomedical Research Networking Centre in Physiopathology of Obesity and Nutrition.

3 Mar 2010

Synta Pharmaceuticals receives FDA approval for resuming elesclomol clinical development

Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today reported that the U.S. Food and Drug Administration (FDA) has approved resuming clinical development of elesclomol, the Company's first-in-class oxidative stress inducer.

2 Mar 2010

UAMS researchers identify age-related mechanism as primary cause of osteoporosis

Marking a shift in decades of thought on the cause of osteoporosis, researchers at the University of Arkansas for Medical Sciences have identified an age-related mechanism - not a decrease of the hormone estrogen - as the primary culprit.

27 Feb 2010

Viral Genetics: Company update

Our mission is to bring new drug compounds to the marketplace. And we've never been in a stronger position to deliver on that promise. We've built the solid foundation needed to take drug therapies from the laboratory to the marketplace. After years in development, we believe several of our most promising compounds are moving closer to clinical trials.

12 Feb 2010

CRT, AstraZeneca announce alliance to develop new anti-cancer drugs

Cancer Research UK's commercialisation and development arm, Cancer Research Technology (CRT), today announced it has teamed up with biopharmaceutical business, AstraZeneca in a major, multi-project alliance, in which around 30 scientists will be focused on creating a stream of new anti-cancer drugs, it is announced today (Sunday).

9 Feb 2010

Scientists are getting closer to prove how cholesterol causes heart disease

By considering molecular-level events on a broader scale, researchers now have a clearer, if more complicated, picture of how one class of immune cells goes wrong when loaded with cholesterol. The findings reported in the February 3rd issue of Cell Metabolism, a Cell Press publication, show that, when it comes to the development of atherosclerosis and heart disease, it's not about any one bad actor-it's about a network gone awry.

3 Feb 2010

Researchers discover new mechanism to burn body fat

Researchers reporting in the February 3rd issue of Cell Metabolism may have a new way to trick the body into consuming more energy. The target in this case is an enzyme that indirectly controls the activity of what the researchers refer to as the "energy master switch." It boils down to this:

2 Feb 2010

Leukemia cells rely on fatty acid metabolism to grow and evade cell death

Leukemia cells, like most cancers, are addicted to glucose to generate their energy, but new research shows for the first time that these cells also rely on fatty acid metabolism to grow and to evade cell death.

28 Jan 2010

Santica Research Labs launches CelluScience Anti-Cellulite Beaute Intensive dietary supplement

More than 85% of women in the U.S. have cellulite. Now, there is a revolutionary new anti-cellulite dietary supplement clinically proven to help target the thighs, hips and gluteal area.

28 Jan 2010

Cornerstone Pharmaceuticals closes $6.17M Series B-4 private equity financing

Cornerstone Pharmaceuticals Inc., a privately held, clinical stage oncology-focused pharmaceutical company, has announced the closing of its Series B-4 private equity financing of $6,175,000. The Company plans to use the proceeds for its on-going phase I/II clinical trials of its lead cancer drug--CPI-613, research and development, and general corporate purposes.

27 Jan 2010

Study: Warburg effect promotes rapid cell proliferation and tumor growth

A team of scientists led by Professor Adrian Krainer, Ph.D., of Cold Spring Harbor Laboratory has discovered molecular factors in cancer cells that boost the production of an enzyme that helps alter the cells' glucose metabolism. The altered metabolic state, called the Warburg effect, promotes extremely rapid cell proliferation and tumor growth. Adrian Krainer, Ph.D.

23 Jan 2010

Health Canada approves Novartis' Afinitor to treat patients with mRCC

Novartis Pharmaceuticals Canada Inc. (Novartis) announced today that Afinitor(R) (everolimus), a once-daily oral cancer treatment, has been approved by Health Canada for patients with metastatic renal cell carcinoma (mRCC), also known as advanced kidney cancer, after failure of initial treatment with VEGF-receptor targeted therapies Sutent(R) (sunitinib) or Nexavar(R) (sorafenib).

20 Jan 2010

Balanced diet and exercise are the only reliable ways to lose weight

It's time to set the record straight. The only reliable way to lose weight is to eat less or exercise more. Preferably both.

7 Jan 2010

ATP-sensitive potassium channel can contribute to fat deposition and obesity, new study says

A new study involving the University of Iowa, Mayo Clinic and two other institutions provides insight on weight control, suggesting that a ATP-sensitive potassium channel critical to survival and stress adaptation can contribute to fat deposition and obesity.

6 Jan 2010

Study reveals molecular mechanism that could lead to new approach in treating obesity

Mayo researchers collaborating with investigators at the University of Iowa, University of Connecticut and New York University (NYU) have discovered a molecular mechanism that controls energy expenditure in muscles and helps determine body weight. Researchers say this could lead to a new medical approach in treating obesity.

5 Jan 2010